Ampio rises on FDA ruling on Zertane questionnaire

NEW YORK -- Shares of Ampio Pharmaceuticals Inc. rose Monday after the company said it is ready to conduct a new clinical trial of its premature ejaculation treatment Zertane.

Ampio said the Food and Drug Administration has questionnaire to be used in pivotal trial of Zertane. The study will measure the duration of sex and the patients' responses to the questionnaire.

Ampio shares rose 36 cents, or 9 percent, to $4.35 in midday trading.

Zertane is Ampio's most advanced drug, and it is also developing a version that combines Zertane with a treatment for impotence. The company is also studying an eye drug called Optina, an inflammation drug called Ampion, and Vasaloc, which treats kidney damage caused by diabetes.

View the original article here

Ampio Pharma says eye drug trial can go ahead

GREENWOOD VILLAGE, Colo. -- Biotech drugmaker Ampio Pharmaceuticals Inc. said Tuesday the Food and Drug Administration accepted its application to start testing the eye drug Optina.

Optina is designed to treat diabetic macular edema, which can cause blurred vision and blindness. Ampio said it plans to start clinical studies of the drug in the first quarter of 2013. Based on earlier FDA decisions, Optina could be approved based on the results of a single successful clinical trial.

Ampio is also studying an inflammation drug called Ampion and premature ejaculation treatments called Zertane and Zertane-ED. The company completed its initial public offering in July, and it does not have any approved drugs.

Shares of Ampio rose 12 cents, or 2.5 percent, to $5.01 in morning trading.

View the original article here